{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T20:53:25Z","timestamp":1794862405618,"version":"4.9.1"},"reference-count":58,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.eururo.2024.10.019","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T01:09:31Z","timestamp":1730855371000},"page":"143-154","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"title":["First and Second-line Treatments in Metastatic Renal Cell Carcinoma"],"prefix":"10.1016","volume":"87","author":[{"given":"Regina","family":"Barragan-Carrillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddy","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee-Maria","family":"Saliby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxine","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Albiges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Bex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Heng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Mejean","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Motzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R.","family":"Plimack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Powles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian I.","family":"Rini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni K.","family":"Choueiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2024.10.019_b0005","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1002\/cncr.34180","article-title":"Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma","volume":"128","author":"Motzer","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2024.10.019_b0010","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/annonc\/mdz056","article-title":"Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Escudier","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2024.10.019_b0015","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines\u00ae): kidney cancer version 1.2024. Plymouth Meeting, PA: NCCN; 2023. https:\/\/www.nccn.org\/guidelines\/guidelines-detail."},{"key":"10.1016\/j.eururo.2024.10.019_b0020","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2002.20.1.289","article-title":"Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma","volume":"20","author":"Motzer","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.10.019_b0025","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor\u2013targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.10.019_b0030","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.10.019_b0035","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.10.019_b0040","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.10.019_b0045","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.10.019_b0050","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.10.019_b0055","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.10.019_b0060","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.annonc.2023.09.3108","article-title":"Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study","volume":"35","author":"Yan","year":"2024","journal-title":"Ann Oncol"},{"issue":"4 Suppl","key":"10.1016\/j.eururo.2024.10.019_b0065","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1200\/JCO.2024.42.4_suppl.363","article-title":"Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): long-term follow-up data from the phase 3 CheckMate 214 trial","volume":"42","author":"Tannir","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.10.019_b0070","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.eururo.2023.06.006","article-title":"Pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 KEYNOTE-426 study","volume":"84","author":"Plimack","year":"2023","journal-title":"Eur Urol"},{"issue":"17 Suppl","key":"10.1016\/j.eururo.2024.10.019_b0075","article-title":"Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426","volume":"41","author":"Rini","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4 Suppl","key":"10.1016\/j.eururo.2024.10.019_b0080","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1200\/JCO.2024.42.4_suppl.362","article-title":"Nivolumab plus cabozantinib (N+C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Results from 55-month follow-up of the CheckMate 9ER trial","volume":"42","author":"Bourlon","year":"2024","journal-title":"J Clin Oncol"},{"issue":"16 Suppl","key":"10.1016\/j.eururo.2024.10.019_b0085","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1200\/JCO.2023.41.16_suppl.4502","article-title":"Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)","volume":"41","author":"Motzer","year":"2023","journal-title":"J Clin Oncol"},{"issue":"15 Suppl","key":"10.1016\/j.eururo.2024.10.019_b0090","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.1200\/JCO.2021.39.15_suppl.4502","article-title":"Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC)","volume":"39","author":"Motzer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.10.019_b0095","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(22)00212-1","article-title":"Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol"},{"issue":"16 Suppl","key":"10.1016\/j.eururo.2024.10.019_b0100","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1200\/JCO.2024.42.16_suppl.4508","article-title":"Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN Renal 101 phase 3 trial","volume":"42","author":"Motzer","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.10.019_b0105","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","article-title":"Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial","volume":"35","author":"Choueiri","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.10.019_b0110","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.10.019_b0115","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMoa2212851","article-title":"Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma","volume":"388","author":"Choueiri","year":"2023","journal-title":"N Engl J Med"},{"issue":"6 Suppl","key":"10.1016\/j.eururo.2024.10.019_b0120","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1200\/JCO.2023.41.6_suppl.605","article-title":"Outcomes by IMDC risk in the COSMIC-313 phase 3 trial evaluating cabozantinib (C) plus nivolumab (N) and ipilimumab (I) in first-line advanced RCC (aRCC) of IMDC intermediate or poor risk","volume":"41","author":"Powles","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.eururo.2024.10.019_b0125","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1200\/JCO.2021.39.6_suppl.319","article-title":"Active therapy or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: the BEYOND study (Meet-Uro 19)","volume":"39","author":"Giorgione","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.10.019_b0130","doi-asserted-by":"crossref","first-page":"e438644","DOI":"10.1200\/EDBK_438644","article-title":"Integrating palliative care into the management of genitourinary malignancies","volume":"44","author":"Masel","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.eururo.2024.10.019_b0135","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.eururo.2022.06.017","article-title":"The role of stereotactic ablative body radiotherapy in renal cell carcinoma","volume":"82","author":"Ali","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.10.019_b0140","doi-asserted-by":"crossref","first-page":"e390038","DOI":"10.1200\/EDBK_390038","article-title":"State of the art: multidisciplinary management of oligometastatic renal cell carcinoma","volume":"43","author":"Dason","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.eururo.2024.10.019_b0145","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.euo.2022.11.003","article-title":"International multi-institutional characterization of the perioperative morbidity of metastasectomy for renal cell carcinoma","volume":"6","author":"Lyon","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2024.10.019_b0150","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.10.019_b0155","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1177\/03008916221138881","article-title":"A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: the BREAKPOINT trial (Meet-Uro trial 03)","volume":"109","author":"Procopio","year":"2023","journal-title":"Tumori J"},{"key":"10.1016\/j.eururo.2024.10.019_b0160","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1001\/jamaoncol.2022.3511","article-title":"Efficacy and safety of telaglenastat plus cabozantinib vs placebo plus cabozantinib in patients with advanced renal cell carcinoma: the CANTATA randomized clinical trial","volume":"8","author":"Tannir","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.eururo.2024.10.019_b0165","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1470-2045(13)70093-7","article-title":"Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial","volume":"14","author":"Motzer","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.10.019_b0170","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1470-2045(19)30735-1","article-title":"Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study","volume":"21","author":"Rini","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.10.019_b0175","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.eururo.2020.08.007","article-title":"Final overall survival results from a phase 3 study to compare tivozanib to sorafenib as third- or fourth-line therapy in subjects with metastatic renal cell carcinoma","volume":"78","author":"Pal","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.10.019_b0180","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.10.019_b0185","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.eururo.2021.12.024","article-title":"Assessing the safety and efficacy of two starting doses of lenvatinib plus everolimus in patients with renal cell carcinoma: a randomized phase 2 trial","volume":"82","author":"Pal","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.10.019_b0190","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/S1470-2045(21)00241-2","article-title":"Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111\/KEYNOTE-146): a phase 1b\/2 study","volume":"22","author":"Lee","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.10.019_b0195","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","article-title":"Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial","volume":"402","author":"Pal","year":"2023","journal-title":"Lancet"},{"issue":"10460","key":"10.1016\/j.eururo.2024.10.019_bib296","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(24)01758-6","article-title":"Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study","volume":"404","author":"Choueiri","year":"2024","journal-title":"The Lancet"},{"key":"10.1016\/j.eururo.2024.10.019_b0210","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel-Lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2024.10.019_b0215","doi-asserted-by":"crossref","first-page":"S1329","DOI":"10.1016\/j.annonc.2023.10.090","article-title":"LBA88 Belzutifan versus everolimus in participants (pts) with previously treated advanced clear cell renal cell carcinoma (ccRCC): randomized open-label phase III LITESPARK-005 study","volume":"34","author":"Albiges","year":"2023","journal-title":"Ann Oncol"},{"issue":"4 Suppl","key":"10.1016\/j.eururo.2024.10.019_b0220","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1200\/JCO.2024.42.4_suppl.361","article-title":"Belzutifan versus everolimus in participants (pts) with previously treated advanced renal cell carcinoma (RCC): Patient-reported outcomes (PROs) in the phase 3 LITESPARK-005 study","volume":"42","author":"Powles","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.10.019_b0225","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S1470-2045(23)00097-9","article-title":"Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study","volume":"24","author":"Choueiri","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.10.019_b0230","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2217\/fon-2022-0802","article-title":"LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1\/PD-L1 therapy","volume":"19","author":"Motzer","year":"2023","journal-title":"Future Oncol"},{"key":"10.1016\/j.eururo.2024.10.019_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2020.100030","article-title":"First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts","volume":"6","author":"Aeppli","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.eururo.2024.10.019_b0240","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.euros.2021.12.007","article-title":"Efficacy and safety of first-line systemic therapy for metastatic renal cell carcinoma: a systematic review and network meta-analysis","volume":"37","author":"Bosma","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.eururo.2024.10.019_b0245","doi-asserted-by":"crossref","first-page":"6687","DOI":"10.1158\/1078-0432.CCR-21-2283","article-title":"Treatment-free survival after immune checkpoint inhibitor therapy versus targeted therapy for advanced renal cell carcinoma: 42-month results of the CheckMate 214 trial","volume":"27","author":"Regan","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2024.10.019_b0250","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S1470-2045(21)00693-8","article-title":"Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial","volume":"23","author":"Cella","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2024.10.019_b0255","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.eururo.2022.06.009","article-title":"Health-related quality of life analysis from KEYNOTE-426: pembrolizumab plus axitinib versus sunitinib for advanced renal cell carcinoma","volume":"82","author":"Bedke","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2024.10.019_b0260","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/bju.12781","article-title":"A novel prognostic model for patients with sarcomatoid renal cell carcinoma","volume":"115","author":"Zhang","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2024.10.019_b0265","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.euo.2024.02.007","article-title":"Stratification of patients with renal cell carcinoma by the abundance of sarcomatoid features reveals differences in survival and the underlying pathobiology","volume":"7","author":"Salgia","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2024.10.019_b0270","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005445","article-title":"Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma","volume":"10","author":"Rini","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"15 Suppl","key":"10.1016\/j.eururo.2024.10.019_b0275","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1200\/JCO.2019.37.15_suppl.4500","article-title":"Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): outcomes in the combined IMDC intermediate\/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study","volume":"37","author":"Rini","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6 Suppl","key":"10.1016\/j.eururo.2024.10.019_b0280","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1200\/JCO.2021.39.6_suppl.308","article-title":"Nivolumab + cabozantinib (NIVO+CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER","volume":"39","author":"Motzer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.10.019_b0285","doi-asserted-by":"crossref","first-page":"1223282","DOI":"10.3389\/fonc.2023.1223282","article-title":"Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms","volume":"13","author":"Gr\u00fcnwald","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.eururo.2024.10.019_b0290","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1200\/JCO.22.00868","article-title":"Management of metastatic clear cell renal cell carcinoma: ASCO guideline","volume":"40","author":"Rathmell","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2024.10.019_b0295","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/2159-8290.CD-24-0102","article-title":"CD70-targeted allogeneic CAR T-cell therapy for advanced clear cell renal cell carcinoma","volume":"14","author":"Pal","year":"2024","journal-title":"Cancer Discov"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824026812?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283824026812?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T15:41:50Z","timestamp":1737646910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283824026812"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0302283824026812"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2024.10.019","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First and Second-line Treatments in Metastatic Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2024.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}